We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Safety of Oral Clemastine - Analysis of Data from Spontaneous Reporting System in Poland.
- Authors
Stanistaw Han; Karlowicz-Bodalska, Katarzyna; Miskiewicz, Katarzyna; Kutycka, Elzbieta; Kuchar, Ernest
- Abstract
Purpose: To analyse the safety of oral clemastine marketed in Poland based on spontaneous adverse event reporting system Methods: We analyzed sales volume and data obtained from the monitoring of spontaneous reports on the adverse effects of Clemastinum Hasco tablets (1.0 mg) and Clemastinum Hasco syrup (0.1 mg/mL) received by the manufacturer (PPF HASCO-LEK S.A. Wroclaw, Poland) and National Monitoring Centre in Warsaw in the period January 2007 to June 2012. The Polish system is mainly based on written reports voluntarily submitted by healthcare professionals. Results: A total of 2,089,717 units of Clemastinum Hasco tablets 1.0 mg and 1,965,340 units of Clemastinum Hasco syrup 0.1 mg/mL were marketed during the period analyzed. Only one spontaneous report on clemastine was registered in the period analyzed. Conclusion: Oral clemastine is a safe medication, rarely causing adverse effects; Nevertheless, the existing spontaneous monitoring system for adverse effects in Poland may not be sensitive enough and therefore, needs improvement.
- Subjects
ANTIHISTAMINES; DRUG side effects; EPIDEMIOLOGY; ORAL medication; DRUG tablets
- Publication
Tropical Journal of Pharmaceutical Research, 2014, Vol 13, Issue 12, p2115
- ISSN
1596-5996
- Publication type
Article
- DOI
10.4314/tjpr.v13i12.24